Cytiva and Pall, two subsidiaries of Danaher Corporation, announced that they will be making a $1.5 billion-investment toward expanding their manufacturing capacity and services. The largest single investment, $600+ million, will go toward chromatography resins. Part of the $600+ million will specifically go toward establishing a new manufacturing site in the United States. Of the remaining sum, $400 million is going toward cell culture media; $300 million toward single-use technologies; and $200 million toward continuing expansion work in various countries. Source: Biopharm International 27/7/2021